Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4mg) and dual agonists (tirzepatide 15mg) produce significant, sustained weight loss (11.8% and 14.7-20.9% respectively) compared to placebo, but discontinuation leads to significant weight recurrence (approx. 2/3 of lost weight).
If you qualify (BMI ≥27 with comorbidity or ≥30), GLP-1 agonists like semaglutide (2.4mg weekly) or tirzepatide (15mg weekly) are highly effective, producing 12-21% weight loss. However, these are chronic treatments; stopping them leads to regaining ~2/3 of the weight. Discuss coverage and long-term commitment with your provider.
StrongSupportsVERY_HIGH confidence
Semaglutide has demonstrated efficacy and safety in patients with overweight or obesity, and is associated with a significant 11.8% body weight reduction compared with placebo (66–71). In patients with obesity, with and without type 2 diabetes, tirzepatide 15 mg was associated with a mean change in body weight of −14.7% and −20.9%, respectively (72, 73)... 1 year after withdrawing from semaglutide 2.4 mg and lifestyle intervention, individuals experienced weight recurrence of a mean of two-thirds of the weight lost after 68 weeks of treatment (77).
Why this rating
Cites multiple high-quality clinical trials (STEP 1, SURPASS) with specific efficacy data.
Source
Tackling the complexity of obesity in the US through adaptation of public health strategies
Jamy D. Ard et al. · Frontiers in Public Health · 2025
narrative_reviewCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →